Enhanced SLAMF7 Homotypic Interactions by Elotuzumab Improves NK Cell Killing of Multiple Myeloma.

Saved in:
Bibliographic Details
Title: Enhanced SLAMF7 Homotypic Interactions by Elotuzumab Improves NK Cell Killing of Multiple Myeloma.
Authors: Pazina T; Blood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.; FSBSI 'Institute of Experimental Medicine,' St. Petersburg, Russia., James AM; Blood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania., Colby KB; Blood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania., Yang Y; Blood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania., Gale A; Blood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania., Jhatakia A; Bristol-Myers Squibb, Princeton, New Jersey., Kearney AY; Bristol-Myers Squibb, Princeton, New Jersey., Graziano RF; Bristol-Myers Squibb, Princeton, New Jersey., Bezman NA; Bristol-Myers Squibb, Princeton, New Jersey., Robbins MD; Bristol-Myers Squibb, Princeton, New Jersey., Cohen AD; Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania. kerry.campbell@fccc.edu adam.cohen@uphs.upenn.edu., Campbell KS; Blood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania. kerry.campbell@fccc.edu adam.cohen@uphs.upenn.edu.
Source: Cancer immunology research [Cancer Immunol Res] 2019 Oct; Vol. 7 (10), pp. 1633-1646. Date of Electronic Publication: 2019 Aug 20.
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 101614637 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2326-6074 (Electronic) Linking ISSN: 23266066 NLM ISO Abbreviation: Cancer Immunol Res Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2326-6074
DOI:10.1158/2326-6066.CIR-18-0579